Autoantibody-mediated agranulocytosis in association with chronic GVHD

Ruck, Sabine; Hilgendorf, Inken; Müller‐Hilke, Brigitte; Kiefel, V.; Junghanß, Christian; Freund, Mathias; Greinix, Hildegard; Wolff, Daniel

doi:10.1038/bmt.2008.173

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cGVHD is initiated when the host immune system encounters the recipient tissues, but as with ADs, the clinical manifestations of cGVHD may take months, or even years, to manifest. There are increasing numbers of clinical reports of an association between transplantation and humoral autoimmunity, and although there can now be little doubt that transplantation may act as a trigger for the development of autoantibodies, their clinical significance and relationship with cGVHD remain to be elucidated (Quaranta et al, 1999;Patriarca et al, 2006;Ruck et al, 2008;Tyndall and Dazzi, 2008;Moon et al, 2009;Lepelletier et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation

Hao

Gao

Sang

et al. 2019

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

We investigated the value of autoantibodies as biomarkers of chronic graft-versus-host disease (cGVHD) by analyzing the autoantibody profiles of 65 patients (34 cGVHD and 31 non-cGVHD) surviving longer than three months after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Autoantibodies to at least one antigen were detected in 45 patients (70.8%), with multiple autoantibodies detected in 30 patients (46.2%). Antinuclear antibodies (ANAs) were the most frequently detected autoantibodies, with a significantly higher prevalence in non-cGVHD patients and cGVHD patients than that in healthy controls (HCs). ANA-nucleolar (ANA-N) was the main immunofluorescence pattern of ANA-positivity in both the non-cGVHD and cGVHD groups. There was a higher prevalence of anti-Ro52-positivity in non-cGVHD and cGVHD patients than in HC. Liver cGVHD was significantly associated with anti-Ro52-positivity. However, cGVHD activity and severity were not associated with the presence of autoantibodies. Similarly, there were no significant differences in overall survival or relapse among the four groups of patients expressing autoantibodies. Our results suggest that autoantibodies have limited value in predicting cGVHD.

show abstract